Vemurafenib is a synthetic small-molecule BRAF kinase inhibitor developed for the treatment of cancers containing specific activating BRAF mutations, particularly the BRAF V600 mutation. It is an orally active targeted anticancer compound and is commercially associated with the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma and other approved oncology applications.
Vemurafenib selectively inhibits certain mutated forms of the BRAF serine/threonine-protein kinase. BRAF is part of the RAF-MEK-ERK signaling pathway, which regulates cellular proliferation and survival. Mutations such as BRAF V600E can result in constitutive activation of this pathway and promote uncontrolled cell growth. Vemurafenib binds to the ATP-binding site of mutant BRAF and inhibits kinase signaling, thereby reducing downstream pathway activity in BRAF-mutated tumor cells.
Vemurafenib is a chemically defined pharmaceutical API with the molecular formula C₂₃H₁₈ClF₂N₃O₃S and a molecular weight of approximately 489.93 g/mol. Its CAS Number is 918504-65-1. The compound is chemically known as propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}amide.
The API occurs in different solid-state forms. Regulatory development identified crystalline Form II as the stable crystalline form. Vemurafenib has very low aqueous solubility, which is an important physicochemical characteristic of the drug substance. The crystalline material is described as a white to almost white powder and has a reported melting point of approximately 271°C.
From a pharmaceutical manufacturing perspective, Vemurafenib requires comprehensive control of chemical identity, assay, water content, inorganic residues, elemental impurities, related substances and residual solvents. Regulatory assessment documentation confirms that the drug substance specification includes identification by IR and HPLC, assay by HPLC, water determination, heavy metals, sulphated ash, residual solvents and HPLC-related impurities.
Vemurafenib API is particularly relevant to targeted oncology development involving BRAF-mutated cancers. Its mechanism distinguishes it from conventional cytotoxic chemotherapy because it is designed to inhibit a specific molecular driver associated with tumor-cell signaling.
For pharmaceutical development, Vemurafenib quality control should include validated analytical procedures capable of distinguishing the active pharmaceutical ingredient from process-related impurities and degradation products. HPLC is particularly important for assay and related-substance determination, while spectroscopic and chromatographic techniques can be used for identity confirmation.
The drug substance specification should also address water and inorganic residue because these attributes can influence the quality and stability of the API. Elemental impurities and residual solvents should be controlled according to the applicable manufacturing process and regulatory requirements.
Vemurafenib is therefore an important oncology API, BRAF inhibitor API and targeted anticancer pharmaceutical ingredient for pharmaceutical research, development and manufacturing. A qualified Vemurafenib API manufacturer and supplier in India should maintain appropriate controls over assay, purity, related substances, water, elemental impurities, residual solvents and physical form.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 99.0–101.0% on anhydrous basis |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 10 ppm |
| Individual Impurity | NMT 0.10% |
| Total Impurities | NMT 0.50% |
| Water Content | NMT 1.0% |
| Melting Point | Approximately 271°C |